Form 8-K - Current report:
SEC Accession No. 0001641172-25-005086
Filing Date
2025-04-16
Accepted
2025-04-16 17:07:30
Documents
14
Period of Report
2025-04-15
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37159
2 ex99-1.htm EX-99.1 11112
  Complete submission text file 0001641172-25-005086.txt   227825

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE awh-20250415.xsd EX-101.SCH 3012
4 XBRL LABEL FILE awh-20250415_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE awh-20250415_pre.xml EX-101.PRE 22358
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3821
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 25843500
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)